Market Research Logo

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2015

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2015’, provides an overview of the Uterine Leiomyoma (Uterine Fibroids)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uterine Leiomyoma (Uterine Fibroids) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) Overview
Therapeutics Development
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
Bayer AG
BioSpecifics Technologies Corp.
Dongkook Pharmaceutical Co., Ltd.
Euroscreen S.A.
Kissei Pharmaceutical Co., Ltd.
Laboratoire HRA Pharma
Novartis AG
Repros Therapeutics Inc.
Takeda Pharmaceutical Company Limited
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
collagenase clostridium histolyticum - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Endometriosis and Uterine Fibroids - Drug Profile
Product Description
Mechanism of Action
R&D Progress
elagolix sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EVE-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LFA-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relugolix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
telapristone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
triptorelin pamoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ulipristal acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vilaprisan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VPEA-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uterine Leiomyoma (Uterine Fibroids) - Recent Pipeline Updates
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Featured News & Press Releases
Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids
Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design
Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis
Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids
Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program
Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya
Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids
Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine
Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2015
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc., H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp., H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Euroscreen S.A., H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Novartis AG, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc., H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Uterine Leiomyoma (Uterine Fibroids) Therapeutics - Recent Pipeline Updates, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2015
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2015
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report